First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
一线单药帕博利珠单抗治疗 PD-L1 阳性（肿瘤比例评分 ≥ 50%）晚期非小细胞肺癌的真实世界研究：对脑转移的影响：一项法国全国多中心队列研究（ESCKEYP GFPC 研究）
期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-022-03232-2
Descourt, Renaud; Greillier, Laurent; Perol, Maurice; Ricordel, Charles; Auliac, Jean-Bernard; Falchero, Lionel; Gervais, Radj; Veillon, Rémi; Vieillot, Sabine; Guisier, Florian; Marcq, Marie; Justeau, Grégoire; Bigay-Game, Laurence; Bernardi, Marie; Fournel, Pierre; Doubre, Hélène; Pinsolle, Julian; Amrane, Karim; Chouaïd, Christos; Decroisette, Chantal
肺癌
肿瘤
肿瘤免疫
神经科学
GFP
PD-L1
细胞生物学
